Personalized cancer vaccines? WTF?

Cancer vaccine developers have seen their fair share of disappointments, and failures have spurred some companies to test their treatments in smaller patient subpopulations. Now, researchers at the University of Connecticut are narrowing their focus even further as they gear up to trial personalized cancer vaccines.

Using genome sequencing to identify the differences between protein sequences--called epitopes--in healthy versus cancerous tissue, they'll start up an initial clinical study for ovarian cancer patients once they nab FDA approval. The team will sequence DNA from the tumors of 15 to 20 women with ovarian cancer, using that information to make a personalized vaccine for each woman.

 

http://www.fiercevaccines.com/story/are-personalized-approaches-solution-troubled-cancer-vaccine-field/2014-10-23?utm_medium=rss&utm_source=rss&utm_campaign=rss

Basically it means that cancer vaccines do not work... Surprised? I am not...

Because they are worth it!

http://www.fiercebiotech.com/story/roche-blueprints-18b-rd-complex-pred/2014-10-22?utm_medium=rss&utm_source=rss&utm_campaign=rssThey're building a new home for John Reed and Roche's ($RHHBY) pRED research group in Basel--and the pharma giant is thinking big. Roche said today that it is committing $1.8 billion to build a new research center in Switzerland that will encompass four new office and lab buildings to house 1,900 R&D staffers.

The first step of the process will involve construction of an in vivo center for animal research, slated for completion in 2018. And Roche--the top R&D spender in the world with a 2013 budget of $10.3 billion--plans to clear away older buildings to make way for a new office tower as part of a wider building plan that will cost a total of $3.2 billion.

Quote of the day

Fake?

We want a war...

http://www.youtube.com/watch?v=rAP1caLoHSs

Size does matters!

That's it!

2014's most successful biotech IPOs

http://www.fiercebiotech.com/special-reports/2014s-most-successful-biotech-ipos
2014's most successful biotech IPOs

The top 10 most expensive drugs of 2013

The top 10 most expensive drugs of 2013 http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013

The fantasy: 'spray-on-skin' for leg ulcers... WTF?

A novel spray-on skin treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body’s own cells to help heal leg ulcers, has failed in a late-stage clinical trial.
The product, known as HP802-247, was viewed by some analysts as a key pipeline asset in the company's advanced wound management division and the Phase III failure is a setback for the healthcare group, which is a regular subject of takeover talk.
The unsuccessful North American trial, announced on Monday, is also something of a surprise, given the promise of earlier studies.
http://in.reuters.com/article/2014/10/13/us-smith-nephew-skin-idINKCN0I20EN20141013?feedType=RSS&feedName=health&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A+reuters%252FINhealth+%2528News+%252F+IN+%252F+Health%2529